CompletedPhase 4

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia

China70 participantsStarted 2016-05

Plain-language summary

The purpose of this study is to evaluate whether autologous stem cell transplantation will improve the survival of patients with high-risk Waldenström macroglobulinemia, compared with conventional chemotherapy.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 70 years\>=Aged \>=18 years
✓. diagnosed with high-risk LPL/WM according to the ISSWM criteria
✓. untreated or mild treated without standard regimens
✓. suitable for ASCT
✓. with life-expectancy more than 3 months.

Exclusion criteria

✕. diagnosed with other malignancies outside B-NHL within one year(including active center neural system lymphoma)
✕. transformed lymphoma
✕. liver or renal function lesion unrelated to lymphoma
✕. serious complications such as uncontrolled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician
✕. HIV positive or active HBV infection or other uncontrolled systematic infection
✕. clinical central nervous dysfunction
✕. serious surgery within 30 days
✕. pregnancy or baby nursing period or un-contracepted child-bearing period woman; 9. allergy to the trail drugs.

What they're measuring

progress-free survival

Timeframe: up to 36 months

Trial details

NCT IDNCT02844361

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-11

View on ClinicalTrials.gov More Waldenström Macroglobulinemia trials